Camlin Fine Sciences Limited (CAMLINFINE) AI Stock Analysis

• Market Cap: ₹42.17B
• Dividend Yield: N/A
• Average Volume (3M): 39.76K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.95
• Revenue Growth: 8.06%
• EPS Growth: 19.90%
• Country: IN
• Employees: 624
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Chemicals - Specialty
• EPS (TTM): 0.20
• Shares Outstanding: 187,921,000
• 10 Day Avg. Volume: 51,734
• 30 Day Avg. Volume: 39,761
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹215.00
• Price Target Upside: 2.02% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 46 Neutral
• Price Target: ₹215.00 ▲(2.02% Upside)

Camlin Fine Sciences Limited faces significant challenges with profitability and cash flow, which are the most impactful factors on its stock score. Technical analysis suggests weak momentum, and valuation metrics are unattractive due to negative earnings. The absence of earnings call data and corporate events limits additional insights.

Camlin Fine Sciences Limited Business Overview & Revenue Model

Company Description

Camlin Fine Sciences Limited, together with its subsidiaries, engages in the research, development, manufacture, and marketing of specialty chemical, ingredients, and additive blend products in India and internationally. It offers shelf-life solutions, which include antioxidants comprises Tertiary Butyl Hydroquinone, Butylated Hydroxy Anisole, and Ascorbyl palmitate; and mold inhibitors, preservatives, acidifiers, antibacterial agents, toxin binders, pellet binders, and growth promoters, as well as natural antioxidants, such as mixed tocopherols, green tea extract, rosemary extract, and acerola extract that are used to enhance the shelf life under the Xtendra and NaSure brands. The company also provides aroma ingredients, including vanillin and ethyl vanillin; and nutraceutical products from fermentation and plant extraction sources. In addition, it offers performance chemicals, such as hydroquinone and catechol; and downstream fine chemicals, including Guaiacol, Veratrole, TBC, MEHQ, HQEE, etc. The company also exports its products. Its products are used in food and beverage, pet food and animal nutrition, biodiesel, aquaculture, rendering, petrochemical, agrochemical, pharmaceutical, polymers, dyes and pigment, biscuits and cookies, chocolate and confectionery, fragrance manufacturing, bakery, flavor, electroplating, and dietary supplement industries. The company was formerly known as Camlin Fine Chemicals Limited and changed its name to Camlin Fine Sciences Limited in August 2011. Camlin Fine Sciences Limited was founded in 1931 and is headquartered in Mumbai, India.

How the Company Makes Money

Camlin Fine Sciences Limited generates revenue through the sale of its specialty chemicals, which are categorized into three main segments: food antioxidants, aroma chemicals, and performance chemicals. The company earns money primarily by supplying these products to various industries such as food and beverages, animal nutrition, and industrial applications. Their key revenue streams include the sale of antioxidants used in food preservation, which helps extend the shelf life of products, and aroma chemicals used in enhancing flavors and fragrances. Significant partnerships with global distributors and end-users, along with a focus on research and development, contribute to the company's earnings by enabling innovation and expansion into new markets.

Camlin Fine Sciences Limited Financial Statement Overview

Summary

Camlin Fine Sciences Limited shows modest revenue growth but faces significant profitability challenges, with consistent net losses and negative cash flow. The balance sheet is stable with moderate leverage, yet cash constraints are evident.

Income Statement

The revenue growth over the last year was modest at 4.48%. However, the company has struggled with profitability, as indicated by a negative net profit margin of -8.34% for the latest year. This marks a deterioration from the previous year's margin, which was also negative. Gross profit margins have improved slightly, but overall profitability remains weak, evidenced by negative net income for the past two years.

Balance Sheet

The debt-to-equity ratio is approximately 0.76, indicating a moderate level of leverage. Return on equity has turned negative due to the recent net losses, which is concerning. However, the equity ratio is relatively strong at 44.53%, providing some asset coverage. The balance sheet indicates stability in the asset base but highlights challenges in profitability.

Cash Flow

Operating cash flow has significantly decreased from the previous year. Free cash flow has turned negative, reflecting challenges in generating cash relative to capital expenditures. The operating cash flow to net income ratio is positive, suggesting operational activities are still generating cash, but the free cash flow to net income ratio is negative, highlighting cash constraints.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	16.67B	16.67B	15.95B	16.71B	14.04B	11.81B
Gross Profit	8.17B	8.17B	6.58B	8.27B	6.34B	5.77B
EBITDA	2.47B	2.18B	487.60M	1.84B	1.79B	1.89B
Net Income	-1.39B	-1.39B	-927.53M	521.06M	606.78M	509.63M
Balance Sheet
Total Assets	20.24B	20.24B	19.52B	20.60B	18.00B	14.82B
Cash, Cash Equivalents and Short-Term Investments	1.92B	1.92B	812.28M	951.90M	1.29B	1.21B
Total Debt	6.81B	6.81B	6.83B	8.01B	6.46B	5.50B
Total Liabilities	11.49B	11.49B	10.95B	12.36B	10.35B	7.68B
Stockholders Equity	9.02B	9.02B	8.65B	8.19B	7.48B	6.43B
Cash Flow
Free Cash Flow	0.00	-157.24M	784.06M	-934.11M	-683.40M	335.07M
Operating Cash Flow	0.00	267.23M	1.39B	508.98M	1.45B	1.17B
Investing Cash Flow	0.00	-753.50M	-664.98M	-1.25B	-2.49B	-1.33B
Financing Cash Flow	0.00	724.43M	-859.72M	596.58M	1.36B	386.27M

Camlin Fine Sciences Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 210.75
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:CAMLINFINE, the sentiment is Negative. The current price of 210.75 is below the 20-day moving average (MA) of 218.22, below the 50-day MA of 233.65, and above the 200-day MA of 196.73, indicating a neutral trend. The MACD of -1.98 indicates Negative momentum. The RSI at 40.71 is Neutral, neither overbought nor oversold. The STOCH value of 23.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:CAMLINFINE.

Camlin Fine Sciences Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADVENZYMES	69 Neutral	37.39B	27.31	9.23%	1.60%	5.89%	-1.30%
PREMEXPLN	66 Neutral	32.48B	88.44	11.67%	0.08%	62.92%	33.94%
ROSSARI	64 Neutral	35.94B	26.59	11.50%	0.08%	11.77%	-1.14%
NEOGEN	62 Neutral	40.52B	120.44	4.41%	0.07%	11.14%	-11.15%
BALAMINES	59 Neutral	48.02B	31.54	8.54%	0.75%	-12.28%	-22.10%
CAMLINFINE	46 Neutral	₹42.17B	―	―	―	8.06%	19.90%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%

Camlin Fine Sciences Limited Corporate Events

Camlin Fine Sciences Announces Postal Ballot and E-voting Notice

Camlin Fine Sciences Limited has announced the publication of a notice regarding a Postal Ballot and Remote E-voting process in newspapers, as part of its compliance with SEBI regulations. This announcement indicates the company’s commitment to regulatory transparency and shareholder engagement, potentially impacting its corporate governance practices and stakeholder relations.